Reply to P Collin et al [2]

American Journal of Clinical Nutrition

Volumn 86, Issue 1, 2007, Pages 260-261

  Catassi, Carlo ^a   Fasano, Alessio ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUTEN;

CELIAC DISEASE; DIETARY INTAKE; DRUG EXPOSURE; FEASIBILITY STUDY; FOOD AND DRUG ADMINISTRATION; HUMAN; LETTER; LIFESTYLE; NUTRIENT AVAILABILITY; PALATABILITY; PRACTICE GUIDELINE; PROTEIN INTAKE; PROTEIN RESTRICTION; QUALITY OF LIFE; SAFETY; VALIDITY; WHEAT;

EID: 34447275216     PISSN: 00029165     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajcn/86.1.260a     Document Type: Letter

References (4)

1. Catassi C, Fabiani E, Iacono G, et al. A prospective, double-blind, placebo-controlled trial to establish a safe gluten threshold for patients with celiac disease. Am J Clin Nutr 2007;85:160-6.
2. Zhang J. FDA calls for standards on gluten. Wall Street Journal 2007 Jan 23:page D3.
3. Gibert A, Espadaler M, Angel Canela M, Sanchez A, Vaque C, Rafecas M. Consumption of gluten-free products: should the threshold value for trace amounts of gluten be at 20, 100 or 200 p.p.m.? Eur J Gastroenterol Hepatol 2006;18:1187-95.
4. US Department of Health and Human Services, Food and Drug Administration.. Food labeling; gluten-free labeling of foods. Fed Reg 2007;72(14):21 CFR Part 101.